Advicenne S.A. (EPA:ALDVI)

Market Cap	21.86M
Revenue (ttm)	3.33M
Net Income (ttm)	-8.83M
Shares Out	12.28M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,753
Average Volume	26,467
Open	1.840
Previous Close	1.850
Day's Range	1.684 - 1.850
52-Week Range	0.827 - 3.060
Beta	1.14
RSI	39.39
Earnings Date	Mar 27, 2025

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, as well as cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2023, Advicenne's revenue was 3.27 million, an increase of 10.98% compared to the previous year's 2.94 million. Losses were -7.03 million, -38.70% less than in 2022.